7780 Stock Overview
Engages in the research and development of healthy food products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Daiken Biomedical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$155.00 |
| 52 Week High | NT$192.00 |
| 52 Week Low | NT$81.00 |
| Beta | 0 |
| 1 Month Change | -11.93% |
| 3 Month Change | -13.41% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7780 | TW Personal Products | TW Market | |
|---|---|---|---|
| 7D | -5.8% | 1.4% | -0.3% |
| 1Y | n/a | -25.1% | -2.0% |
Return vs Industry: Insufficient data to determine how 7780 performed against the TW Personal Products industry.
Return vs Market: Insufficient data to determine how 7780 performed against the TW Market.
Price Volatility
| 7780 volatility | |
|---|---|
| 7780 Average Weekly Movement | 4.0% |
| Personal Products Industry Average Movement | 6.8% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in TW Market | 10.2% |
| 10% least volatile stocks in TW Market | 4.9% |
Stable Share Price: 7780 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: Insufficient data to determine 7780's volatility change over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20 | n/a | certifications.nutrasource.ca/certified-products/brand?id=DABI |
Daiken Biomedical Co., Ltd. engages in the research and development of healthy food products. The company is based in Taipei, Taiwan. Daiken Biomedical Co., Ltd.
Daiken Biomedical Co., Ltd. Fundamentals Summary
| 7780 fundamental statistics | |
|---|---|
| Market cap | NT$9.30b |
| Earnings (TTM) | NT$113.87m |
| Revenue (TTM) | NT$1.23b |
81.7x
P/E Ratio7.5x
P/S RatioIs 7780 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7780 income statement (TTM) | |
|---|---|
| Revenue | NT$1.23b |
| Cost of Revenue | NT$430.28m |
| Gross Profit | NT$803.11m |
| Other Expenses | NT$689.24m |
| Earnings | NT$113.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.90 |
| Gross Margin | 65.11% |
| Net Profit Margin | 9.23% |
| Debt/Equity Ratio | 32.3% |
How did 7780 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield35%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/18 06:19 |
| End of Day Share Price | 2025/04/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daiken Biomedical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.